New Molecule could Effectively Treat Chemotherapy-Induced Neuropathy

New Molecule could Effectively Treat Chemotherapy Induced Neuropathy

The molecule has a novel mode of action and it could be first treatment against this neurological complication, which does not have effective treatment currently.

Peripheral neuropathy is major disadvantage of certain chemotherapeutics used in the treatment of cancers. It is characterized by tingling, numbness, pain or alterations in the functionality of patients. Cancer patients have to go through this complication despite having a demonstrated negative impact on the quality of life, increasing care expenses, and preventing the complete and effective administration of the cytostatic treatment with the potential decrease of survival chances.

Researchers from Neuro-Oncology Unit of Bellvitge University Hospital – Catalan Institute of Oncology have reported that new molecule is capable of preventing progression of peripheral neuropathy induced by chemotherapy in cancer patients. It can significantly help in reducing symptoms of neuropathy in colon cancer.  Researchers at the HUB-ICO-IDIBELL Unit detected a new molecule developed by the Catalan laboratory Esteve as a candidate to prevent this adverse effect. “Through a public-private partnership, we have been able to design a Phase 2b clinical trial, which has allowed us to get a great deal of scientific information – effect on pain, pathophysiology – and draw conclusions as to the potential of the drug in the prevention of neuropathies during cytostatic treatment”, said explains Dr. Bruna, lead of the study.

According to Targeted Cancer Therapies Market report published by Coherent Market Insights, chemotherapy has adverse effects on cancer patients, which include neuropathy. In any case, improving pain control and reducing the occurrence of severe neuropathy is undoubtedly the most prominent benefit of the development of this novel drug. As a result of the study, it was observed that cancer patients who took new drug showed low symptoms of disorders regarding nerve dysfunction. “Given the usual pace of clinical trials and drug agencies following fast-track approval processes in severe or orphan pathologies, this new drug could potentially reach the market soon, since it would be the first available treatment to avoid this type of neuropathy. In addition, it has other medical uses as a non-opioid analgesic”, said Bruna.

The molecule has a novel mode of action and it could be first treatment against this neurological complication, which does not have effective treatment currently.
Peripheral neuropathy is major disadvantage of certain chemotherapeutics used in the treatment of cancers. It is characterized by tingling, numbness, pain or alterations in the functionality of patients. Cancer patients have to go through this complication despite having a demonstrated negative impact on the quality of life, increasing care expenses, and preventing the complete and effective administration of the cytostatic treatment with the potential decrease of survival chances.
Researchers from Neuro-Oncology Unit of Bellvitge University Hospital – Catalan Institute of Oncology have reported that new molecule is capable of preventing progression of peripheral neuropathy induced by chemotherapy in cancer patients. It can significantly help in reducing symptoms of neuropathy in colon cancer. Researchers at the HUB-ICO-IDIBELL Unit detected a new molecule developed by the Catalan laboratory Esteve as a candidate to prevent this adverse effect. “Through a public-private partnership, we have been able to design a Phase 2b clinical trial, which has allowed us to get a great deal of scientific information – effect on pain, pathophysiology – and draw conclusions as to the potential of the drug in the prevention of neuropathies during cytostatic treatment”, said explains Dr. Bruna, lead of the study.
According to Targeted Cancer Therapies Market report published by Coherent Market Insights, chemotherapy has adverse effects on cancer patients, which include neuropathy. In any case, improving pain control and reducing the occurrence of severe neuropathy is undoubtedly the most prominent benefit of the development of this novel drug. As a result of the study, it was observed that cancer patients who took new drug showed low symptoms of disorders regarding nerve dysfunction. “Given the usual pace of clinical trials and drug agencies following fast-track approval processes in severe or orphan pathologies, this new drug could potentially reach the market soon, since it would be the first available treatment to avoid this type of neuropathy. In addition, it has other medical uses as a non-opioid analgesic”, said Bruna.

You may be interested

Mobile Health Apps and Solutions Market Industry Insights, Dynamic Growth and Revenue Forecast 2018-2026
Business
Business

Mobile Health Apps and Solutions Market Industry Insights, Dynamic Growth and Revenue Forecast 2018-2026

Albert R - October 19, 2018

Mobile Health Apps and Solutions Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of…

Drug Abuse Treatment Market – Launch and approval of novel drugs is projected to fuel market growth over the forecast period
Business
Business

Drug Abuse Treatment Market – Launch and approval of novel drugs is projected to fuel market growth over the forecast period

Mohit Joshi - October 19, 2018

Coherent Market Insights released a new market study on 2018-2026 Drug Abuse Treatment Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages…

Elderly and Disabled Assistive Devices Market in the US Market: Business Opportunities, Current Trends, Market Challenges & Industry Analysis By 2026
Business
Business

Elderly and Disabled Assistive Devices Market in the US Market: Business Opportunities, Current Trends, Market Challenges & Industry Analysis By 2026

Albert R - October 19, 2018

The Elderly and Disabled Assistive Devices Market is expected to have a highly positive outlook for the next five years 2018 – 2026 according to a recently…

Most from this category